FRM
KITE

Fox Run Management’s Kite Pharma, Inc. KITE Stock Holding History

Fox Run Management’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5,100
Closed -$314K – 626
2015
Q4 		$314K Buy
+5,100
New +$359K 0.24% 149

Other funds holding KITE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fox Run Management's KITE Position: Q1 2016 in Review

Fox Run Management sold out of Kite Pharma, Inc. (KITE) in Q1 2016, closing a stake of 5,100 shares — an estimated $314K sold.

Fox Run Management first reported a position in KITE in Q4 2015 and held it in 1 quarter. The position peaked at $314K in Q4 2015. 171 funds tracked by Wall St. Rank hold KITE as of Q1 2016.

  • Fox Run Management reported no remaining Kite Pharma, Inc. position as of Q1 2016 after selling out during the quarter.
  • Fox Run Management sold 5,100 Kite Pharma, Inc. shares in Q1 2016, an estimated $314K.
  • Fox Run Management first reported a position in Kite Pharma, Inc. in Q4 2015 and held it in 1 quarter.
  • Fox Run Management's Kite Pharma, Inc. position peaked at $314K in Q4 2015.
  • 171 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q1 2016.

Based on Fox Run Management's 13F filing for Q1 2016, filed 18 Apr 2016.